arrow
A

Anne F. Luetkemeyer

university of california
H指数:31
被引数:6,929

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Distinct T cell correlates of COVID-19 risk before and after a second booster in previously SARS-CoV-2 infected versus naïve COVAIL trial participants

先前感染SARS-CoV-2与未感染的COVAIL试验参与者在二次加强针前后COVID-19风险的T细胞相关性差异

2026-10-060
OAAI
Performance Evaluation of the Xpert® HCV test on Fingerstick Blood in a Prospective Observational Clinical Study at CLIA-Waived Sites in the United States

在美国CLIA豁免点进行的前瞻性观察性临床研究中,指血Xpert® HCV检测的性能评估

2026-03-130
OA
It's Been a Very Liberating Experience: Doxycycline Postexposure Prophylaxis for Sexually Transmitted Infection Prevention and Experiences With Sexual Pleasure by Men Who Have Sex With Men

这是一次非常解放的经历:针对男男性行为者性传播感染预防的后暴露预防性使用多西环素及性快感体验

2025-12-010
PRE
Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study

奥贝德西韦在低风险、非住院COVID-19患者中的有效性与安全性(OAKTREE):一项III期、随机、双盲、安慰剂对照研究

2025-07-140
PRE
Short Course Therapy With Glecaprevir/Pibrentasvir for Early Hepatitis C Virus Infection: PURGE-C

glecaprevir/pibrentasvir短期疗法治疗早期丙型肝炎病毒感染:PURGE-C

2025-07-010
PRE
Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial
2025-02-171
OAAI
Impact of doxycycline post-exposure prophylaxis for sexually transmitted infections on the gut microbiome and antimicrobial resistome

多西环素暴露后预防性传播感染对肠道微生物组和抗菌药物耐药组的影响

2024-10-030
OAAI
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial
2024-09-261
PRE
Doxycycline as Postsexual Exposure Prophylaxis: Use, Acceptability, and Associated Sexual Health Behaviors Among a Multi-Site Sample of Clinical Trial Participants

多西环素作为性接触后的预防: 临床试验参与者的多地点样本中的使用,可接受性和相关的性健康行为

2024-04-017
PRE
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial
2023-08-2819
OAAI
Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial
2023-08-101
OA
Hepatic steatosis and nonalcoholic fatty liver disease are common and associated with cardiometabolic risk in a primary prevention cohort of people with HIV
AIDS
IF3.1
2023-07-287
PRE
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial
2023-04-1011
OA